Dementia and Alzheimer Disease

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 11, 2023.

Pharmacokinetic results indicated that ACD856 has a suitable pharmacokinetic profile for further development with a rapid absorption, dose-dependent exposure, and a favorable metabolic profile.

The double-blind, placebo-controlled trial assesses change from baseline in the weekly average of daily self-reported worst pain intensity scores after 14 weeks of treatment.

Catch up on any of the neurology news headlines you may have missed over the course of July 2023, compiled all into one place by the NeurologyLive® team.

The associate professor of neurology at the Indiana University School of Medicine discussed the screening paradigm for Alzheimer disease, and the reluctancy to use new digital tools over traditional methods. [WATCH TIME: 6 minutes]

Concentrations of Aß42 and Aß40 were substantially higher in those with amyloid-ß-negative, tau-positive status compared with Aß-negative, tau-negative patients.

Here's some of what is coming soon to NeurologyLive® this week.

As a recap from AAIC 2023, get caught up on some of the latest news in neurology as the NeurologyLive® team shares some of our data updates.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders.

A group of experts in the care of patients with neurological conditions—Kumar B. Rajan, PhD; Christina Jensen-Dahm, MD, PhD; Nicole Fowler, PhD; Nicholas Ashton, PhD; Jazmyn Muhammad, BS—shared their perspectives on hot topics of treatment and management in Alzheimer disease from the 2023 Alzheimer's Association International Conference.

Neurology News Network for the week ending August 5, 2023. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 4, 2023.

The director at the Foundation for the National Institutes of Health discussed relevant biomarkers for Alzheimer disease and their role as novel therapeutics continue to emerge. [WATCH TIME: 5 minutes]

Boris Kantor, PhD, associate research professor of neurobiology, and Ornit Chiba-Falek, PhD, professor in neurology, both faculty at Duke University, discussed research on an innovative epigenome therapy targeting the APOE gene, a significant genetic risk factor for Alzheimer disease.

The director of research for internal medicine and geriatrics at Indiana University School of Medicine discussed the advantages digital assessments bring to clinics, and what role they will play in the coming years. [WATCH TIME: 3 minutes]

Because its gut-acting and gut-restricted, the safety profile of DGX-001 was considered advantageous in comparison to traditional neuropsychiatric therapies.

Sharon L. Rogers, PhD, chief executive officer at AmyriAD Therapeutics, discussed AD101, a novel drug that targets the core symptoms in Alzheimer disease, and highlighted the importance of symptom management strategies.

Sleep stage percentages were not associated with global cognition across cohorts, while patients with mild to severe OSA displayed poorer global cognitive function.

Here's some of what is coming soon to NeurologyLive® this week.

Research shows that carrying the APOE e4 variant significantly increases lifetime risk for late-onset Alzheimer disease, and additional evidence suggests that lowering the variant expression may be a promising therapeutic target for the disease.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is epilepsy and seizure disorders.

The associate research professor of neurobiology at Duke University discussed an innovative epigenome editing approach that shows promising prospects for patient improvement, disease prevention, and potential use in Alzheimer disease prophylactic work. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 28, 2023.

Andreas Muehler, MD, and Hella Kohlhof, PhD, provided answers on a recently published analysis showing considerable activation of nuclear receptor related 1 with vidofludimus calcium, an agent in development for various forms of multiple sclerosis.

The chief executive officer at INmune Bio discussed a unique approach from a phase 1 study targeting neuroinflammation in the brain to improve cognitive abilities and maintain memory. [WATCH TIME: 5 minutes]

Maria Carrillo, PhD, chief science officer for the Alzheimer's Association, talked about the release of the updated diagnostic guidelines for Alzheimer disease, which incorporate plasma-based biomarkers.

Results suggest that the high burden of cerebral amyloid angiopathy-related lesions most likely underlies the 30%-60% incidence of amyloid-related imaging abnormalities in APOE e4/4 carriers treated with approved amyloid therapies.

Based on a collection of data from clinical trials in Alzheimer disease, the best way to represent and translate the findings to meaningful benefits is through the use of multiple frameworks.

The chief medical officer at Athira Pharma talked about an exploratory phase 2 trial that showcased the correlation between biomarkers for Alzheimer disease hallmarks and neuroinflammation. [WATCH TIME: 5 minutes]

The director at the Foundation for the National Institutes of Health provided perspective on the effective ways to utilize currently available biomarkers for Alzheimer disease research.